Sponsor & Developer Portfolio
The University of Texas Medical Branch, Galveston
Clinical development pipeline, platform architecture, and registered trial tracking for The University of Texas Medical Branch, Galveston vaccine candidates.
1
Candidates
1
Target Diseases
1
Linked Studies
Development Phase Distribution
Phase 3 Clinical Trial: 1
Platform Technologies
Biological (unspecified platform): 1
Target Pathogens & Indications
HPV
Vaccine Pipeline Candidates (1)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Phase 3 Clinical Trial
ctgov-9-valent-hpv-vaccine-2-doses-alternate-timing-the-university-of-
9-valent HPV vaccine, 3 doses standard timing
Target: HPV
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2026-08 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.